Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Bottom-Up

<ul>
<li>In FY24, <a href="https://www.smartkarma.com/entities/morepen-laboratories-ltd" target="_blank" data-smartkarma-citation="entities:13092:1" rel="noopener">Morepen Laboratories (MORE IN)</a> achieved revenue, EBITDA, and PAT growth of 20%, 101% and 150%, YoY, respectively, driven by medical devices and API businesses.</li>
<li>Business has stabilized in FY24 and Morepen is seeing fresh buying of medical devices. With expanding capacity, glucometer and BP monitor are expected to maintain ~30% growth momentum.</li>
<li>Morepen aims to expand API product portfolio and geographic reach, while maintaining global leadership positioning in six key widely used API products.</li>
</ul>


In FY24, Morepen Laboratories (MORE IN) achieved revenue, EBITDA, and PAT growth of 20%, 101% and 150%, YoY, respectively, driven by medical devices and API businesses.
Business has stabilized in FY24 and Morepen is seeing fresh buying of medical devices. With expanding capacity, glucometer and BP monitor are expected to maintain ~30% growth momentum.
Morepen aims to expand API product portfolio and geographic reach, while maintaining global leadership positioning in six key widely used API products.


Morepen Laboratories (MORE IN): Strong Performance in FY24; Positive Momentum to Sustain